Structure Therapeutics (GPCR) drew attention after publishing Phase 2b ACCESS trial data for its oral GLP-1 candidate aleniglipron in Nature Medicine, alongside a detailed presentation at the American Diabetes Association’s 86th Scientific Sessions.

The latest data release has arrived against a mixed price backdrop, with the stock at US$42.93 after a strong 7 day share price return of 14.24%. This contrasts with a weaker 90 day share price return of 24.22% and a year to date share price return of 36.98%, while the 1 year total shareholder return of 98.02% and 3 year total shareholder return of 34.24% point to earlier strength and more recent momentum loss.

If obesity drug pipelines are on your radar, this is a good moment to widen your research and review 40 healthcare AI stocks

So with strong trial headlines, a share price that has recently pulled back after earlier gains, and no current revenue, should you see GPCR as undervalued based on its obesity pipeline or assume the market is already pricing in future growth?

Preferred Price to Book of 2x: Is It Justified?

On the latest figures, Structure Therapeutics trades at a P/B of 2x, which sits below both the US Pharmaceuticals industry average of 2.2x and a peer average of 7.2x.

P/B compares the company’s market value with its net assets on the balance sheet. It is often used for early stage or unprofitable biopharma stocks where earnings are not yet meaningful. For GPCR, this lens focuses attention on how much investors are paying for its asset base and pipeline relative to what is recorded on the books.

With no current revenue and ongoing losses, the discount to both industry and peer P/B levels suggests the market is not assigning a premium to GPCR’s balance sheet or pipeline at this point. Instead, pricing appears more conservative compared with peers.

Compared with the US Pharmaceuticals industry average P/B of 2.2x and a peer average of 7.2x, GPCR’s 2x multiple stands at a clear discount, indicating more restrained expectations are embedded in the current price than in many comparable stocks.

Result: Price-to-book of 2x (ABOUT RIGHT)

However, the company still carries clear risks, including ongoing losses of US$141.202m and full reliance on yet to be commercialised obesity and fibrosis programs.

Next Steps

If this mix of caution and optimism leaves you undecided, take a moment to review the full picture of risks and potential rewards for yourself with 1 key reward and 3 important warning signs

Looking for more investment ideas?

Do not stop with a single stock. Broaden your watchlist now using focused screens that surface opportunities you might otherwise miss.

• Target potential bargains by checking companies that combine quality with attractive pricing through the 44 high quality undervalued stocks.
• Prioritise resilience by reviewing companies with stronger balance sheets and fundamentals via the solid balance sheet and fundamentals stocks screener (48 results).
• Stay ahead of the crowd by scanning lesser known opportunities with solid metrics using the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.